In a similar setup, a range of PI3K/AKT/mTOR-directed therapies (e.g. pan-PI3K inhibitors, mTORC1 inhibitors, mTORC1/2 inhibitors and dual PI3K/mTORC1/2 inhibitors) have been tested in long-term cultures of patient-derived B-ALL cells. Here, AKT1 is linked to acute lymphoblastic leukemia.